Company Overview and News
Oh, the trials and tribulations of being in the middle. Think of the poor middle child of the family. The elder sibling gets all sorts of attention as parents fret over getting everything right with their first kid. Then the next child comes along and the parents figure that they have this parenting thing down, so they don’t worry as much.
GNE PAGP GNE PAA GEL BPL
Energy firms with at least 0.71 broker target upside and 2% dividend yield showed midstream firms high on lists led by Blueknight Energy for upside and Sandridge for yield.
NGL ETP.PRC NGL.PRB MMLP SMLP BPL SRLP CCLP GNE ETP CAPL GPP GNE EEP GEL SNMP
It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.
FBU AIR MRP FCREY MGHTF FRCEF ANZFY AIZ GNE MYT FBU ANZLY ANZFF GNE MEZ GEL
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GMA SRHYY ECX BCHEY SYAAF BEPTF BPT GNE UBS SYR UBS.PRDCL GNE GEL ULSGF
Editor's note: Seeking Alpha is proud to welcome Silver Coast Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
GNE CINR GNE GEL
Self-funding has become a buzzword in the MLP space, but is it really translating to MLPs’ capital plans? Admittedly, the shift to self-funding is still in early innings, and the transition will take time. That said, it seems like a logical next step as the MLP space continues to mature. In today’s post, we discuss the impetus behind MLPs’ shift to self-funding and give some examples of MLPs that are pursuing self-funding.
MPLX DCP RMP EPD MPC ALJ GNE EQM ALDW WES GNE MMP GEL
Welcome to the 2018 First Quarter Conference Call for Genesis Energy. Genesis has four business segments: The Offshore Pipeline Transportation Division is engaged in providing critical infrastructure to move oil produced from the long-lived world-class reservoirs from the Deepwater Gulf of Mexico to Onshore Refining Centers. The Sodium Minerals and Sulfur Services Division includes trona and trona-based exploring, mining, processing, producing, marketing and selling activities, as well as the processing of sour gas streams to remove sulfur and refining operations.
GNE XOM GNE GEL
There's considerable trepidation brewing within the senior business community on whether Shane Jones' appointment as Associate Minister for State Owned Enterprises signals another round of knuckle-headed Beehive politics.
GNE ANZLY AIR GNE ANZFF ANZFY MEZ AIZ GEL
* GENESIS ENERGY - “REMAIN ON TRACK WITH OUR PREVIOUSLY ANNOUNCED GUIDANCE FOR VISIBLE, ACHIEVABLE LONG TERM DISTRIBUTION GROWTH” Source text for Eikon: Further company coverage:
GNE GNE GEL
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.
CEN FCREY NZTCF RYM KMD COENF GNE AOTUF CEN KMD GEL KTHDY FBU WBC RHCGF SPKKY NZTCY SPK WEBNF WBK FRCEF COENY WBC FBU RYHTY GNE GTK MEZ
Miller Howard Investments Inc Buys Huntington Bancshares Inc, CenterPoint Energy Inc, Canon Inc, Sells Weyerhaeuser Co, International Paper Co, Cisco Systems Inc
TLLP LBIO INPAP KALU ANDX PTIE BHI GNE VSLR PRMW IP SHLX CNP CAJ CSCO GNE IOVA RCON GEL NPO
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to NZX:GNE / Genesis Energy on message board site Silicon Investor.